• New to Cure CMD?

    This year’s goal is to register the global CMD community.

    Take a moment to register on the CMD International Registry (CMDIR), www.cmdir.org 

    CMDIR in French, German, Spanish and English.  Turkish, Danish and Portuguese coming soon.

  • Join Anne Rutkowski, Cure CMD Chairman at the Burnham Institute

    Cure CMD presents for Rare Disease Day, Feb 26th, at the Burnham Institute (San Diego) for a day of science and advocacy.
    Rare Disease Symposium Flyer

    For more info, email anne.rutkowski@curecmd.com

  • Cure CMD and S.A.M. Team Up to Move CMD Therapies Forward

    2009 Cure CMD grant cycle awarded over $200,000 in CMD science, click here.

    2010 Cure CMD grant application deadline, Sept 15th. For more info, click here

  • Alex rolls Long Branch 1/2 Marathon, New Jersey

    Join Alex and the Cure CMD Team on May 2nd for the Long Branch 1/2 Marathon, New Jersey! 

    Pre- race spaghetti dinner!

    For more info, click here

  • 2010 CMD Family and Affected Individual Conference

    Come learn, connect and meet the CMD community!

    Registration opens on Cure CMD website, April 1st.

    Conference August 14th and15th, Childrens Hospital of Philadelphia, with welcome dinner, Friday, August 13th..

  • Cure CMD Cookbook

    We are creating a Cure CMD Cookbook!

    You can support CMD research simply by sending in your favorite recipes.

    Click here to learn more.


Aidan’s Story

AidanAidan was born in April 2009. We were so thankful that he arrived safely and healthy. Aidan was 7 lbs 14oz — much smaller than his brother Craig who was 9lbs 2oz when he was born in 2003. The first 2 months while on maternity leave, I cherished the days I had with Aidan. Craig was in kindergarten for about three hours and I was happy to have that time to spend with Aidan. Continue reading Aidan’s Story


Cure CMD Research News

Feb 4, 2010: 2009 NIH Funding Estimates for Muscular Dystrophy

The FY2009 estimates of funding by research, condition, and disease categories were released on the NIH RePORT site yesterday. Total FY2009 funding for muscular dystrophy was $66M from the regular NIH appropriation and an additional $17M from the ARRA program. Muscular dystrophy funding level was at $56M in FY2008. More…

Feb 3, 2010: CMD Drug Discovery Meeting

The CMD High Throughput Screen meeting at National Chemical Genomics Center (NCGC) provided the opportunity to discuss CMD targets, development and optimization of target specific assays and expanded screening to NCGC. The meeting set the goal to identify 2 CMD target assays and begin high throughput screening using NCGC resources by 2011. More…

Jan 18, 2010: Seeking Qualified Applicant for Muscle Disease Tenure Track Position

The Iowa Center for Muscular Dystrophy Research seeks outstanding candidates for tenure-track positions at any rank. Successful candidates are expected to establish independent laboratories focusing on skeletal muscle biology and disease. More…

Jan 18, 2010: Muscle Disease Postdoctoral Position Available in Paris

A postdoctoral position is available at the INSERM-UPMC-Paris VI U787-Myology Group, Institut de Myologie, Groupe Hospitalier Pitié-Salpêtrière (Paris), from March 1st 2010.

The candidates must have a Ph.D. and a strong background either in cell biology/muscle physiology or in molecular biology. Previous experience in microscopy and/or epigenetics will be an important asset.

More…

Dec 15, 2009: Cure CMD and S.A.M. team up to move CMD therapies forward!

Cure CMD announces terrific progress towards identifying treatment options in the CMDs!

Together, Cure CMD and S.A.M will fund grants to evaluate 5 promising CMD drug candidates: an NFKappaB inhibitor, laminin 111, a muscle specific IgF upregulator, N-acetyl cysteine and calcium handling compounds. A separate effort to identify disease biomarkers specific to merosin deficient CMD will also be funded. More…

Research News Archive


Current Trials and Studies

Jan 6, 2010: Merosin Deficient (MDC1A) Clinical Study

Dr. Jim Collins at Cincinnati Children’s Hospital Medical Center (CCHMC) will launch a 1 year trial, Jan/2010- Dec/2010, to identify biomarkers in Merosin Deficient CMD (MDC1A). Dr. Collins and Dr. Carsten Bonnemann at the Children’s Hospital of Philadelphia (CHOP) will enroll infants and children, 0-10 years, with Merosin Deficient CMD.
Contact: Shengyong Hu or Paula Morehart (Division of Neurology, Cincinnati Children’s Hospital Medical Center)
Phone: 513-636-3202 or 513-636-7451
Email: shengyong.hu@cchmc.org More…

Dec 29, 2009: BIO-NMD Study: Biomarkers for Collagen VI Myopathies and Duchenne muscular dystrophy

The BIO-NMD consortium, led by the University of Ferrara’s Dra. Alessandra Ferlini will focus current funding on identifying biomarkers in the Collagen VI myopathies and Duchenne muscular dystrophy. The 3 year project is currently funded through Dec 2012. The study will first evaluate muscle tissue biospecimens available through the EuroBioBank, and then move to evaluate blood and urine specimens for disease specific biomarkers. Preliminary biomarkers identified during the first 18 months, will subsequently be validated in prospective patient cohorts as part of the study.
More…

Trials and Studies Archive


Medical Headlines from Other Websites

Feb 8, 2010: Researchers Report That Tβ4 Increases Skeletal Muscle And May Have A Role In The Treatment Of Duchenne Muscular Dystrophy

Regenerx Biopharmaceuticals, Inc. (NYSE Amex:RGN) announced today that a research team in Washington, D.C. has found that dystrophin-deficient Mdx mice, treated twice a week for six months with Tβ4, showed a significant increase in skeletal muscle regenerating fibers compared to untreated mice. No effects related to muscle function or fibrosis and no adverse reactions were observed in the mice...

Feb 7, 2010: AVI BioPharma’s Drug Candidate AVI-5038 Receives European Orphan Drug Designation For Duchenne Muscular Dystrophy

AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, announced that it received an orphan drug designation from the Committee for Orphan Medical Products of the European Medicines Agency (EMEA) for AVI-5038, a drug candidate being developed by AVI for the treatment of Duchenne Muscular Dystrophy (DMD). DMD is a genetic muscle-wasting disease caused by failure to produce dystrophin...

Medical Headlines Archive


  • Donate
  • Congenital Muscular Dystrophy

    A group of diseases causing muscle weakness at birth. Several defined genetic mutations cause muscles to break down faster than they can repair or grow. A child with CMD may have various neurological or physical impairments. Some children never gain the ability to walk, while others lose the ability as they grow older. Learn more...
  • Register Now!
  • Events

  • Register Now!
  • Navigation

    Show Sub-Pages | Hide Sub-Pages